Podcast

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment

Elizabeth Yeu, MD, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of TP03 for the treatment of patients diagnosed with Demodex blepharitis.

Elizabeth Yeu, MD, a cornea cataract and refractive surgeon at Virginia Eye Consultants, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of a new investigational therapeutic from Tarsus Pharmaceuticals called TP03 (lotilaner ophthalmic solution 0.25%), for the treatment of patients diagnosed with Demodex blepharitis.

See more ASCRS coverage

Listen to more EyePod episodes

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
CIME 2025: Neda Shamie, MD, on expanding options in pharmacological presbyopia management
© 2025 MJH Life Sciences

All rights reserved.